ArticleJournal of thoracic disease2026
Immunocyte phenotypes underlying the causal autoimmune features in narcolepsy type 1.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Narcolepsy is a neurological sleep disorder associated with immune response. However, the autoimmune basis for narcolepsy remains unclear. This study aimed to evaluate the causal relationship between immune cells and narcolepsy type 1 (NT1). Methods: We used a two-sample Mendelian randomization (MR) method to investigate the associations between 731 immune cell traits and NT1 based on a genome-wide association study (GWAS) database from the FinnGen consortium. The inverse-variance weighted (IVW) method was used as the primary method, followed by sensitivity analyses, including the MR-Egger intercept test, Cochran's Q test, and MR pleiotropy residual sum and outlier (MR-PRESSO). Additional mediation analysis was conducted to investigate the mediating effect of 91 cytokines on immune cells to facilitate the immune processes in NT1. Results: Immune cell traits showed significant causal associations with NT1. Risk-associated traits mainly involved human leukocyte antigen-DR (HLA-DR)-related monocyte phenotypes, T-cell-related traits, natural killer (NK) cell-related traits, and natural killer T (NKT) cell-related traits, whereas protective traits mainly involved CD4+ T-cell-related, plasmacytoid dendritic cell-related, monocyte-related, and B-cell-related phenotypes. Overall, ten immune cell traits were associated with an increased risk of narcolepsy, whereas five were associated with a reduced risk. Mediation analysis further indicated that interleukin-6 (IL-6) mediates the immune-inflammatory pathway linking monocyte-related traits to NT1. These findings remained consistent in all sensitivity analyses. Conclusions: Our study identified immunophenotypes that are related to the development of NT1, providing insight into the autoimmune pathogenesis of NT1 and subsequent immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.